CN102872134B - Application of Houttuynoid D in drug for treating laryngocarcinoma - Google Patents
Application of Houttuynoid D in drug for treating laryngocarcinoma Download PDFInfo
- Publication number
- CN102872134B CN102872134B CN 201210419543 CN201210419543A CN102872134B CN 102872134 B CN102872134 B CN 102872134B CN 201210419543 CN201210419543 CN 201210419543 CN 201210419543 A CN201210419543 A CN 201210419543A CN 102872134 B CN102872134 B CN 102872134B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- drug
- laryngocarcinoma
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid D in preparing a drug for treating laryngocarcinoma, belonging to the technical field of the new use of the drug. Houttuynoid D is found to have obvious inhibition effect on the growth of human laryngocarcinoma cell lines HEP-2, TU686, M2e and M4e through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid D can be used for preparing the anti-laryngocarcinoma drug and has excellent prospects in development and application. The use of Houttuynoid D in preparing the anti-laryngocarcinoma drug involved in the invention is disclosed for the first time; the framework type of Houttuynoid D is a brand new framework type; and Houttuynoid D has an unexpectedly high inhibition activity for the laryngocarcinoma cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid D, relate in particular to the application of Houttuynoid D in the anti-laryngeal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid D that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes in preparation treatment laryngeal carcinoma medicine that the present invention relates to, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously laryngeal carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid D in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid D in the anti-laryngeal carcinoma medicine of preparation, and the structural formula of Houttuynoid D is shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid D also has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.51 ± 0.05 μ M, 0.33 ± 0.09 μ M, 0.39 ± 0.06 μ M and 1.19 ± 0.12 μ M.Therefore, Houttuynoid D can for the preparation of anti-laryngeal carcinoma medicine, have good development prospect.
The purposes of the Houttuynoid D that the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of tongue obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid D involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid D_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid D tablet involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid D capsule involved in the present invention:
Get 20 and digest compound Houttuynoid D, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid D to the growth inhibited effect of people's laryngeal cancer cell strain
1. method: the cell that is in the growth logarithmic (log) phase: people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid D of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid D has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e.This chemical compound suppresses the IC of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e growth
50Value is respectively: 0.51 ± 0.05 μ M, 0.33 ± 0.09 μ M, 0.39 ± 0.06 μ M and 1.19 ± 0.12 μ M.
Shown by above-described embodiment, Houttuynoid D of the present invention has good inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU 686, M2e and M4e.Prove thus, it is active that Houttuynoid D of the present invention has anti-laryngeal carcinoma, can be for the preparation of anti-laryngeal carcinoma medicine.
Claims (1)
1.Houttuynoid the application of D in preparation treatment laryngeal carcinoma medicine, described compound H outtuynoid D structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419543 CN102872134B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for treating laryngocarcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419543 CN102872134B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for treating laryngocarcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872134A CN102872134A (en) | 2013-01-16 |
| CN102872134B true CN102872134B (en) | 2013-10-23 |
Family
ID=47473805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419543 Expired - Fee Related CN102872134B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid D in drug for treating laryngocarcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872134B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1744887A (en) * | 2003-02-04 | 2006-03-08 | 株式会社益力多本社 | Breast cancer-resistant protein inhibitor |
| CN1880328A (en) * | 2006-04-30 | 2006-12-20 | 重庆大学 | Preparation method of hyperin and hypericin of Hypericum perforatum |
-
2012
- 2012-10-27 CN CN 201210419543 patent/CN102872134B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1744887A (en) * | 2003-02-04 | 2006-03-08 | 株式会社益力多本社 | Breast cancer-resistant protein inhibitor |
| CN1880328A (en) * | 2006-04-30 | 2006-12-20 | 重庆大学 | Preparation method of hyperin and hypericin of Hypericum perforatum |
Non-Patent Citations (2)
| Title |
|---|
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with NovelSkeletons from Houttuynia cordata;Shao-Dan Chen et al.;《ORGANIC LETTERS》;20120313;第14卷(第7期);第1772-1775页 * |
| Shao-DanChenetal..HouttuynoidsA-E Anti-Herpes Simplex Virus Active Flavonoids with NovelSkeletons from Houttuynia cordata.《ORGANIC LETTERS》.2012 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872134A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102861064B (en) | Application of Houttuynoid E in preparing medicine for treating laryngocarcinoma | |
| CN102861069B (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102861065A (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102895248A (en) | Application of Houttuynoid A in drugs for treating laryngocarcinoma | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102872117A (en) | Application of Houttuynoid D in medicament for treating gastric cancer | |
| CN102872110A (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer | |
| CN102872142A (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872138A (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872119A (en) | Application of Houttuynoid D in medicament for treating colorectal cancer | |
| CN102872070A (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FENG MINGSHAN Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141203 Address after: 226400 No. three, No. 41, Haihe Beach village, Yuan Zhen, Jiangsu County, Rudong Patentee after: Feng Mingshan Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |